trastuzumab emtansine
Selected indexed studies
- Trastuzumab emtansine: mechanisms of action and drug resistance. (Breast Cancer Res, 2014) [PMID:24887180]
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. (Br J Cancer, 2020) [PMID:31839676]
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. (J Clin Oncol, 2018) [PMID:29989854]
_Worker-drafted node — pending editorial review._
Connections
trastuzumab emtansine is a side effect of
Sources
- Trastuzumab emtansine: mechanisms of action and drug resistance. (2014) pubmed
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. (2020) pubmed
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. (2018) pubmed
- Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer. (2020) pubmed
- Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. (2020) pubmed
- Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. (2021) pubmed
- Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. (2023) pubmed
- Trastuzumab emtansine: first global approval. (2013) pubmed
- Trastuzumab emtansine in breast cancer. (2013) pubmed
- The role of ado-trastuzumab emtansine in current clinical practice. (2021) pubmed